A series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients.
In patients with type 2 diabetes and peripheral artery disease who undergo revascularization, cardiovascular and renal benefits of the agents were confirmed without increased risk of limb amputation.
Singapore: A meta-analysis of 15 randomized controlled trials of SGLT2 inhibitors for diabetes and non-diabetes patients, showed no significant difference in amputation risk for the various SGLT2.